Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | HTR1F | P30939 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 5/20 | 0.31 |
| ▸ | TOP2A | P11388 | 3/20 | 0.30 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30006217 | 1.00 | GRM2 (0.36) | GRM2HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL16821909 | 0.75 | GLA (0.37) | HTR1AHTR1DHTR1BHTR1FSCD | |
| SCHEMBL23648384 | 0.74 | OPRM1 (0.36) | GRM2SCD | |
| SCHEMBL21636511 | 0.72 | HTR6 (0.40) | GRM2 | |
| SCHEMBL28839286 | 0.70 | HTR2A (0.48) | HTR1AHTR1DHTR1BHTR1FSCD | |
| SCHEMBL21624211 | 0.70 | LPL (0.33) | HTR1AHTR1DHTR1BHTR1FSCD | |
| SCHEMBL30005846 | 0.70 | LPL (0.33) | HTR1AHTR1DHTR1BHTR1FSCD | |
| SCHEMBL31437974 | 0.70 | HTR1A (0.35) | HTR1AHTR1DHTR1BHTR1FSCD | |
| SCHEMBL23883491 | 0.68 | KCNH2 (0.42) | — | |
| SCHEMBL30335333 | 0.68 | KCNH2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | GRUENENTHAL GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-05-14 | — | — | US | disclosed |
| EP-4090660-B1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-31 | — | — | EP | disclosed |
| EP-3823970-B1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-03 | — | — | EP | disclosed |
| CN-112673009-B | Substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-112771046-B | Other substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-12-15 | — | — | US | disclosed |
| EP-4090660-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2022-11-23 | — | — | EP | disclosed |
| EP-3823971-B1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021144439-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-07-22 | — | — | WO | disclosed |
| US-20210163491-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-06-03 | — | — | US | disclosed |
| EP-3823970-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3823971-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-05-26 | — | — | EP | disclosed |
| US-20210139488-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünethal GmbH (DE) | 2021-05-13 | — | — | US | disclosed |
| CN-112771046-A | Other substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-10981918-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2021-04-20 | — | — | US | disclosed |
| CN-112673009-A | Substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2021-04-16 | — | — | CN | disclosed |
| WO-2020016452-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016453-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139488-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | GRM2 59/4885HTR1A 593/4885HTR1D 806/4885 |
| US-20210163491-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | NR3C1, GRK5, NR3C2 | GRM2 46/4885HTR1A 524/4885HTR1D 735/4885 |
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | GRM2 43/4885HTR1A 485/4885HTR1D 717/4885 |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | NR3C1, GRK5, NR3C2 | GRM2 46/4885HTR1A 524/4885HTR1D 735/4885 |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | NR3C1, GRK5, NR3C2 | GRM2 46/4885HTR1A 524/4885HTR1D 735/4885 |
| US-10981918-B2 | Further substituted triazolo quinoxaline derivatives | NR3C1, GRK5, NR3C2 | GRM2 46/4885HTR1A 524/4885HTR1D 735/4885 |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | NR3C1, NR3C2, GRK5 | GRM2 59/4885HTR1A 593/4885HTR1D 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.